» Articles » PMID: 26968641

Characteristics of 10-year Survivors of High-grade Serous Ovarian Carcinoma

Overview
Journal Gynecol Oncol
Date 2016 Mar 13
PMID 26968641
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years.

Methods: A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded.

Results: The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57years (range 37-84years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis.

Conclusions: LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes.

Citing Articles

Disease-free survival of 15 years after primary surgery in a patient with advanced high-grade serous ovarian cancer: a case report and literature review.

Shi Y, Zhu S, Shan J, Xu Y Front Oncol. 2025; 15:1468196.

PMID: 39931084 PMC: 11807797. DOI: 10.3389/fonc.2025.1468196.


Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer.

Wang Y, Yang Y, Guo B, Li X, Tuersun R, Cao Y Front Oncol. 2025; 14:1512339.

PMID: 39868369 PMC: 11758227. DOI: 10.3389/fonc.2024.1512339.


New anti-ovarian cancer quinolone derivatives acting by modulating microRNA processing machinery.

Felicetti T, Di Iacovo N, Della Fazia M, Piobbico D, Pieroni S, Pacetti M RSC Med Chem. 2024; .

PMID: 39399313 PMC: 11467779. DOI: 10.1039/d4md00649f.


The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.

Sarkar S, Saha S, Swarnakar A, Chakrabarty A, Dey A, Sarkar P J Ovarian Res. 2024; 17(1):159.

PMID: 39095849 PMC: 11296390. DOI: 10.1186/s13048-024-01482-5.


Advances in ovarian tumor stem cells and therapy.

Chen B, Liu J Cell Biochem Biophys. 2024; 82(3):1871-1892.

PMID: 38955927 DOI: 10.1007/s12013-024-01385-8.


References
1.
Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

2.
Akeson M, Jakobsen A, Zetterqvist B, Holmberg E, Brannstrom M, Horvath G . A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer. 2009; 19(1):116-23. DOI: 10.1111/IGC.0b013e3181991b13. View

3.
LaChance J, Choudhri A, Sarti M, Modesitt S, Jazaeri A, Stukenborg G . A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol. 2011; 121(1):2-7. DOI: 10.1016/j.ygyno.2010.12.365. View

4.
Vaughan S, Coward J, Bast Jr R, Berchuck A, Berek J, Brenton J . Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10):719-25. PMC: 3380637. DOI: 10.1038/nrc3144. View

5.
Barlin J, Yu C, Hill E, Zivanovic O, Kolev V, Levine D . Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2011; 125(1):25-30. DOI: 10.1016/j.ygyno.2011.12.423. View